Kiora Pharmaceuticals, Inc. KPRX
2.63
(0.04)
(1.50%)
as of 25 Sep
- Market cap
- $11.8M
- P/E
- 0.0×
Follow KPRX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | 1.51 | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | 0.68 | — | — | — | 6.98 | 7.32 | 9.60 | 27.69 | 0.00 |
P/FCF ratio |
— | 1.49 | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | (5.67) | — | — | — | (13.29) | (12.27) | (8.27) | (10.82) | (7.07) |
P/B ratio |
— | 0.50 | — | — | — | 2.33 | 4.79 | 1.85 | 0.00 | 0.00 |
Price to Tangible BV |
— | 0.67 | — | — | — | 0.00 | 32.88 | 5.09 | 0.00 | 0.00 |
EV/Sales |
— | (0.75) | — | — | — | 6.70 | 6.45 | 4.96 | 13.95 | 0.00 |
EV/EBITDA |
— | 0.00 | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | (1.64) | — | — | — | (2.98) | (3.43) | (0.79) | (1.22) | (1.30) |
EV/FCF |
— | (1.64) | — | — | — | (2.95) | (3.41) | (0.79) | (1.22) | (1.29) |
Quick Ratio |
5.62 | 4.60 | 2.76 | 2.24 | 5.21 | 0.64 | 2.67 | 2.08 | 0.53 | 0.50 |
Current Ratio |
5.99 | 4.94 | 2.90 | 2.35 | 5.59 | 0.87 | 3.06 | 2.19 | 0.57 | 0.57 |
Net Debt/EBITDA |
1.33 | (5.78) | 0.20 | 0.49 | 0.76 | 0.13 | 0.54 | 0.74 | 0.54 | 0.27 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.45% | 1.82% | 0.00% | 0.00% | 0.03% | 0.17% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.03 | 0.00 | 0.00 | 0.00 | (0.05) |
Asset Turnover |
0.00 | 0.64 | 0.00 | 0.00 | 0.00 | 0.00 | 0.22 | 0.12 | 0.03 | 0.07 |
Operating CF/Net income |
0.92 | 2.38 | 0.73 | 0.77 | 0.78 | 1.07 | 1.15 | 1.00 | 0.49 | 0.63 |
Capex/Depreciation |
(4.47) | (0.05) | 0.00 | 0.15 | (0.02) | (0.60) | 0.00 | (0.52) | (1.92) | (2.12) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (51.74%) | 22.56% | (148.94%) | (104.54%) | (113.30%) | (83.93%) | (91.23%) | (308.49%) | 1,171.64% | (463.52%) | |
| (35.68%) | 14.32% | (80.55%) | (70.00%) | (77.72%) | (53.99%) | (58.19%) | (75.64%) | (109.98%) | (138.72%) | |
ROIC |
0.00% | 0.00% | (215.23%) | (141.35%) | (130.56%) | (48.66%) | (156.13%) | (727.17%) | 0.00% | 0.00% |
Return on Tangible Assets |
(59.51%) | 15.17% | (419.17%) | (304.33%) | (184.71%) | 3,012.20% | (242.51%) | (232.13%) | 209.20% | 428.21% |
Average Days of Receivables |
0.00 | 19.85 | 0.00 | 0.00 | 0.00 | 2,745.04 | 0.67 | 4.06 | 21.23 | 29.34 |
Research and Development Expense of Revenue |
0.00% | 48.95% | 0.00% | 0.00% | 0.00% | 29,471.07% | 200.65% | 487.49% | 2,535.07% | 1,258.40% |
Selling, General and Administrative Expense of Revenue |
0.00% | 34.60% | 0.00% | 0.00% | 0.00% | 38,502.48% | 164.02% | 268.77% | 1,137.77% | 835.74% |
Intangible Assets out of Total Assets |
0.09 | 0.18 | 0.64 | 0.58 | 0.53 | 0.87 | 0.56 | 0.40 | 0.38 | 0.56 |
Share Based Compensation of Revenue |
0.00% | 4.10% | 0.00% | 0.00% | 0.00% | 5,982.64% | 31.73% | 52.97% | 213.57% | 76.35% |
Graham Net Nets |
— | 1.49 | — | — | — | (0.17) | 0.03 | 0.19 | (0.49) | (0.41) |
Graham Number |
— | 18.11 | — | — | — | 0.00 | 0.00 | 0.00 | 9,198.31 | 6,144.57 |
Earnings Yield |
— | 66.38% | — | — | — | (30.30%) | (22.06%) | (70.94%) | (83.90%) | (89.85%) |
Free Cash Flow Yield |
— | 66.92% | — | — | — | (32.55%) | (25.87%) | (65.78%) | (41.44%) | (58.04%) |
Revenue per Share |
0.00 | 4.14 | 0.00 | 0.00 | 0.00 | 0.95 | 305.23 | 250.38 | 156.73 | 418.31 |
Operating CF per Share |
(2.39) | 2.21 | (17.76) | (128.27) | (398.34) | (571.66) | (926.57) | (1,643.11) | (2,487.88) | (5,258.25) |
Capex per Share |
(0.03) | 0.00 | 0.00 | 0.08 | (2.38) | (1.57) | 0.00 | (3.03) | (14.23) | (6.87) |
Free Cash Flow per Share |
(2.42) | 2.21 | (17.76) | (128.19) | (400.72) | (573.23) | (926.57) | (1,646.14) | (2,502.12) | (5,265.12) |
Cash per Share |
4.10 | 6.92 | 4.56 | 73.37 | 293.09 | 92.63 | 429.17 | 1,212.76 | 3,002.31 | 2,272.00 |
Shareholders Equity per Share |
3.87 | 6.65 | 11.36 | 140.31 | 544.00 | 760.13 | 752.56 | 1,353.98 | (741.12) | (205.87) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.87 | 6.65 | 11.36 | 140.31 | 544.00 | 760.13 | 752.56 | 1,353.98 | (741.12) | (205.87) |
Free Cash Flow |
(10.07) | 8.55 | (9.56) | (10.42) | (10.74) | (7.34) | (8.15) | (10.86) | (6.51) | (8.42) |
Working Capital |
18.12 | 23.70 | 3.10 | 4.41 | 7.38 | (0.26) | 2.91 | 4.61 | (6.37) | (3.15) |
Capital Expenditures |
(0.11) | (0.01) | — | 0.01 | (0.06) | (0.02) | — | (0.02) | (0.04) | (0.01) |
Net Current Asset Value |
13.62 | 18.98 | (2.86) | 0.41 | 3.44 | (3.85) | 0.83 | 3.13 | (7.77) | (5.91) |
EV/EBIT |
— | 0.00 | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | 0.00 | 1.66 | 0.00 | 0.01 | 0.09 | 0.02 |
Net Profit Margin |
0.00% | 22.44% | 0.00% | 0.00% | 0.00% | (56,709.09%) | (264.21%) | (654.25%) | (3,243.66%) | (1,993.64%) |
Price to Operating Income |
— | 2.83 | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.27 | 23.73 | 6.40 | 0.75 | 55.18 | 1.09 | 3.08 | 0.89 | 0.35 | 0.14 |
Cash ROIC |
(30.27%) | 16.28% | (111.68%) | (60.35%) | (47.72%) | (65.64%) | (78.57%) | (64.27%) | (110.88%) | (254.41%) |
Accounts Receivable Turnover |
0.00 | 10.97 | 0.00 | 0.00 | 0.00 | 0.25 | 230.56 | 78.50 | 10.52 | 1.36 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | — | — | — | — |
Average Receivables |
2.09 | 1.46 | 1.71 | 0.95 | 0.31 | 0.05 | 0.01 | 0.02 | 0.04 | 0.49 |
Average Payables |
0.74 | 0.31 | 0.61 | 0.58 | 0.30 | 0.32 | 0.14 | 0.38 | 1.06 | 0.91 |
Average Assets |
30.37 | 25.10 | 16.20 | 19.40 | 17.72 | 12.71 | 12.20 | 14.29 | 12.02 | 9.62 |
Average Common Equity |
20.94 | 15.93 | 8.76 | 12.99 | 12.15 | 8.18 | 7.78 | 3.50 | (1.13) | 2.88 |
Columns are period end dates